QA/QC & Analytical Techniques In-Depth Focus 2020
Read articles on validating rapid microbial methods according to regulatory requirements and how solid-state NMR spectroscopy can be used to analyse pharmaceuticals in this in-depth focus.
List view / Grid view
Articles
Guide to Outsourcing
Welcome to European Pharmaceutical Review’s Guide to Outsourcing. In this edition, Eurofins Scientific, SGS Life Sciences, Charles River Laboratories, ACCI, Eurofins Amatsi Group and Thermo Fisher Scientific showcase their unique outsourcing services and discuss how they stand out from the competition.
European Pharmaceutical Review Issue 5 2020
In this issue you can find articles discussing the supply chain implications of Trump's 'Buy American' order, guidance on how to identify and justify starting materials for regulatory approval by both the EMA and FDA, as well as some of the latest developments in oral biologic drug delivery techniques. Also…
Speeding processes and enhancing compliance with pharmacovigilance automation
Dr John Price explains how life sciences companies are making progress with pharmacovigilance automation and how a new study of pharmaceutical organisations has uncovered potential for improvement in the capture of adverse event data.
Who will receive COVID-19 vaccines first?
EPR’s Hannah Balfour discusses some of the proposed COVID-19 vaccine distribution plans and how medicinal nationalism and supply deals could prevent “fair and equitable access” to COVID-19 vaccines.
Reality check: is robotic process automation a panacea for transforming regulatory affairs?
Regulatory operations are burdened by resource-draining document and data processing tasks, but is robotic process automation the definitive solution? If not, where does it have greatest application and appeal – and how can life sciences firms exploit the full benefits? Agnes Cwienczek scrutinises the technology’s potential.
Communicating with healthcare providers in the time of COVID-19
AJ Ploszay, IQVIA’s Vice President of Digital Strategy, discusses how COVID-19 has accelerated digital transformation and driven the adoption of digital detailing.
How can virtual pharma companies de-risk new product launches?
Christoph Krähenbühl outlines five considerations for virtual pharmaceutical companies when launching a new drug product.
Return to work for life sciences: an evolving challenge
Helen Farr, a Partner at Taylor Wessing, discusses the hurdles that life science businesses must tackle to bring employees back to work safely; whether that be working remotely or returning to the lab.
Linking health and lifetime exposures through biomarkers in breath
Dr Jonathan Lawson explains why detecting and monitoring exposures and the body’s response from breath could be the key to predicting future health issues.
The future of label management is with intelligent automation
Kiran Chinnalla and Julian Backhouse explain why automation for labelling in pharma can help the industry to remain compliant in the face of regulatory changes.
Post-Brexit product supply: which way next for pharma?
Cecilia Avram details the requirements for pharma companies post-Brexit and provides practical pointers on minimising the disruption to cross-border product availability as new rules come into force.
Transforming pathology with RFID could save the NHS millions
This article explores how implementing Radio Frequency Identification (RFID) technology could help NHS pathology services cope with the challenges of the COVID-19 pandemic.
How will clinical trials change in light of COVID-19?
Barbara Lopez Kunz from the Drug Information Association (DIA) discusses how COVID-19 has impacted clinical trials.
The rush to create a vaccine to combat COVID-19 highlights the need to equip researchers with digital solutions
In this article Phoebe Chubb outlines some of the digital solutions that are enabling researchers to continue their work remotely or with social distancing measures, including the Electronic Lab Notebook, Internet of Things (IoT) and automation.
